---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-020043"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T06:01:17.930118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MAIA announces peer-reviewed publication validating second-gen ateganosine prodrugs

## Summary
- Data published in Nucleic Acids Research (Vol. 53, Issue 12, June 26, 2025) on novel telomere-targeting dinucleotide prodrugs.
- Lead candidates MAIA-2022-12 and MAIA-2021-20 showed strongest in vivo anticancer efficacy and immune-memory responses.
- Combination with immune checkpoint inhibitor yielded significantly lower IC50 and superior efficacy vs monotherapy.
- Company plans to advance one candidate into human clinical trials after completing GLP-toxicity studies.

## SEC filing metadata
- accession: 0001641172-25-020043
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225020043/0001641172-25-020043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225020043/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-020043
- JSON: https://secwatch.observer/filing/0001641172-25-020043.json
- Plain text: https://secwatch.observer/filing/0001641172-25-020043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.